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Following the demonstration of the superior validity of human papillomavirus (HPV) tests in screening for cervical cancer and the
arrival of highly efficacious HPV 16 and 18 vaccines, cervical cancer prevention enters a time of sustainable introduction in developing
countries. Multidisciplinary efforts and novel protocols are being developed, and challenging situations are being faced to make
cervical cancer, still the number two cancer in women worldwide, an eradicable condition.
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The provocative title proposed by the editors of the British Journal
of Cancer could have at first sight, a quick and intuitive answer: we
will need both. We need human papillomavirus (HPV) vaccines to
significantly reduce the health care burden currently required for
cervical cancer prevention, and we need screening because of the
limitations of current HPV vaccines both in their lack of
therapeutic effect (thus not protecting women with an ongoing
neoplastic processes) and in their limited number of HPV types
(thus leaving to evolve some 25–30% of cervical cancer cases
related to HPV types other than 16 or 18). However, the answer
only applies in scenarios in which screening is already developed
and reasonably efficient. In populations without adequate screen-
ing, one could equally argue that HPV vaccines at affordable prices
are the only realistic option. While these arrive, more efficient
screening schemes, for example with low-cost HPV tests, requiring
fewer visits or strategies involving rapid intervention like ‘screen
and treat’ protocols, remain the only option for currently living
adult women. Moreover, should polyvalent vaccines (including
some five–eight HPV types) result in extending protection against
more than 90%þ of the oncogenic HPV types, vaccination alone
would be the answer for both scenarios. Thus, a complex answer to
an apparent straightforward question.
PHASE III HPV VACCINATION TRIALS
With the publication of the key short-term results of the two major
Phase III trials of HPV vaccines, the perspective of tackling cervical
cancer prevention with vaccination has been unambiguously open.
While recognising the limitations of the still moderate (5–6 years)
follow-up in a few tens of thousand young women, two vaccines to
date have shown high efficacy, safety, immunogenicity, long-term
duration of protection and a strong suggestions of induction of
immune memory (Harper et al, 2006; Garland et al, 2007;
Paavonen et al, 2007; The Future II Study Group, 2007).
A number of clinically relevant issues remain to be fully
described, including the magnitude and the HPV spectrum
included in the cross protection effect, and the long-term effects
of each of the HPV vaccines on cancer protection and safety.
However, to solve these questions, it is unavoidable to continue the
studies for additional follow-up time and the organisation of large
Phase IV studies, some of which are already in place.
The currently available vaccines offer full protection to HPV 16-
and 18-naı ¨ve women for these two HPV types that cause an
estimated 70% of cervical cancer and a slightly lower fraction of its
precursors. Once the cross protection impact is fully described and
the geographical variation of the HPV types in cervical cancer is
better known, these estimates will likely increase in some areas to
perhaps 75–80%. Human papillomavirus 16 and 18 account for a
higher proportion of cervical adenocarcinomas, in the range of
80–85% (Castellsague et al, 2006), the histological subgroup
that more easily escape detection by cytology-based screening
practices.
Table 1 shows a selection of the established qualitative findings
thus far on both HPV vaccines. Notice that the Gardasil
s program
has already communicated results of its 2-year follow-up in the per
protocol population, evaluating efficacy in HPV DNA-naive
women at study entry. In contrast, the Cervarix
s Phase III
program has only published a prespecified, interim report
including the efficacy analyses on the intention-to-treat popula-
tion, thus including women with HPV and low squamous
intraepithelial lesions (LSIL) at recruitment and a follow-up time
of 15 months.
NEW CENTRE OF GRAVITY OF CERVICAL CANCER
PREVENTION: HPV VACCINE IMPLEMENTATION
AND ACHIEVEMENT OF VACCINATION COVERAGE
On a worldwide scale, the centre of gravity of cervical cancer
prevention has shifted towards a more established mindset in the
field of vaccinology such as ensuring production and access to
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www.bjcancer.comHPV vaccines and devising the logistics to ensure wide coverage of
the target populations. The Expanded Program of Immunization
(EPI) is probably one of the most successful public health efforts in
place. Figure 1 shows the estimated worldwide coverage of infants
with three doses of DTP (diphtheria, tetanus and pertussis).
Globally, the programme ensures vaccination to 70–75% of the
children, and the socioeconomic gap between the wealthiest and
the poorest countries is in the order of 25–30%, while the gap in
terms for example of Gross National Product (GNP) and other
health indicators is several fold higher (Figure 1). Vaccination of
infants is thus feasible in developing countries and vaccination
programmes such as the EPI have developed and maintained in
place a considerable infrastructure and logistics network. Vaccina-
tion of adolescent in contrast might represent the greatest
challenge in many developing populations, and several explana-
tory and demonstration projects are now underway (http://
www.path.org/news/).
Public health researchers thus have an important task ahead,
namely to organise the trials that will guide how to best evaluate
and, if appropriate, to integrate HPV vaccines within the structure
of the EPI. These will certainly take time and should address issues
such as routes of administration (i.e., injection vs oral), number of
doses required (as well as antigen amount per dose), immune
response and duration of protection when administered in these
age groups, and tolerability and safety when administered with
other EPI vaccines. The need and the opportunity of a booster dose
latter in life (i.e., at the time of presenting to the EPI stations with
their first baby) should also be evaluated.
Alternatives such as the deployment of a platform for
vaccination of adolescents (for example, based on schools) could
be considered in some countries with adequate infrastructure.
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Figure 1 Expanded Program of Immunization 1980–2005 DTP3þ coverage by level of development.
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Figure 2 World population prospects for women X15 years.
Table 1 Key results from phase III trials of HPV vaccines
Vaccine name Gardasil
s Cervarix
s
Time of follow-up 36 months
(advanced)
15 months
(interim)
HPV types included 6, 11, 16, 18 16, 18
Efficacy HPV 16 or 18 CIN 2+ Proven Proven
Efficacy HPV 16 CIN 2+ Proven Proven
Efficacy HPV 18 CIN 2+ Proven Not yet proven
a
Efficacy 16 or 18 CIN 2 Proven Proven
Efficacy 16 or 18 CIN 3 Proven Not yet proven
a
Therapeutic efficacy None None
Efficacy on VIN 2/3 Proven Not yet reported
Efficacy on VAIN 2/3 Proven Not yet reported
Efficacy on genital warts Proven Not in target
Safety at 6 years follow-up Safe
b Safe
c
Tolerability Acceptable Acceptable
Cross protection (persistent HPV
infection)
6 months 12 months
Cross protection (lesions) Reported Not yet reported
Duration of protection
d 5–6 years 5–6 years
Immunogenicity in preadolescents Proven Proven
Immunogenicity in older women Proven Proven
Immune memory at 6 years Proven Not yet reported
CIN¼cervical intraepithelial neoplasia; HPV¼human papillomavirus.
aProven in
combined analysis of Phase II and III trials.
bIn postlicensing evaluation (http://
www.who.int/vaccine_safety/en/).
cIn clinical trials.
dCorresponds to duration of trials
in 2007.
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SOLUTION
The population of women in the world continues to increase.
Figure 2 shows the predictions for the period 2000–2050 and
clearly indicates the expected growth of the female population
(ages 15þ years) in developing countries and a stable prediction
in the developed countries. By age groups, these estimates reflect
for girls 10–14 years and women 15–24 years, a plateau in the
developing countries and a decrease in the younger populations in
developed countries, largely in the age groups 15–24 years. With
these population estimates, largely attributable to the increased life
expectancy in women in developing countries, the International
Agency for Research on Cancer (IARC) prediction on the number
of cases of cervical cancer anticipated by 2020, all other things
being equal, is of an increase of 40% globally. The 40% increase in
cervical cancer cases is again dramatically driven by socio-
economic status, and countries in Africa, Latin America and Asia
are predicted to increase the number of cases by 50–55%. Europe
and North America will also experience a modest increase in the
number of cases in the order of 6% in Europe and of 23% in
Northern America (Ferlay et al, 2004).
The number of women in any 1-year age cohort aged between 10
and 14 years has been estimated to be close to 60 million
(Figure 3). Of these, some 52 millions (87%) live in develo-
ping countries. Vaccination of the 5-year preadolescent cohorts
aged 10–14 years would require approximately 1 billion doses of
HPV vaccine (accounting for a 10% waste). Should a catch-up
strategy be put in place, increasing the vaccination target to
women 10–25 years would increase the vaccine requirements for
the initial vaccination rounds to a target of up to 15 billion doses.
There is a clear need to address early in the process the phasing
stages of this introduction and, most importantly, to understand
with vaccine manufacturers how these quantities can be produced,
where are the strategic production countries and the time it will
take to put vaccines into their target delivery points. These
parameters are needed to anticipate the time scale in which
worldwide HPV vaccine introduction will be realistically an
achievable goal.
Human papillomavirus vaccines have a cost in 2007 that exceeds
the current possibilities of many countries. It is thus anticipated
that for some time after introduction, access to vaccination will
also reflect the different opportunities related to socioeconomic
status. Previous experience with the introduction of the hepatitis B
virus vaccine in developing countries has documented that vaccine
cost is an essential component of a successful introduction and a
determinant of the time to introduction in may parts of the world
(Kane et al, 2006).
Figure 3 shows a speculative anticipation on the age and social
groups that are likely to first receive HPV vaccines in developed
and developing countries, outside the organised Phase IV trials
and demonstration projects. The predictions are largely based on
the initial recommendations to vaccinate preadolescent and
adolescent girls (Centers for Disease Control and Prevention,
2007). With this admittedly speculative evidence, one can
anticipate that in developed countries (Figure 3A), adolescent
groups will receive systematic vaccination in the context of public
health-supported programmes and will reach significant coverage
within a relatively short time period. Some amount of vaccine will
also be administered to a less controlled on-demand population of
all ages largely in the private sector. In developing countries
(Figure 3B), women are likely to first access HPV vaccines in the
private sector across all age groups within the higher socio-
economic strata and only latter, access to vaccine will cascade to
wider segments of the adolescent groups and to the general
population. The process is likely to get accelerated when vaccine
availability and lower pricing generalises. Systematic adolescent
vaccination in developing countries will gradually occur in the
future, perhaps related to a first vaccination round within the EPI
vaccination programme. On these grounds, it is important that
additional information on vaccine efficacy and duration of
protection when given to infants is made available by researchers
(Table 2).
It is thus plausible that, unless a definite and specific massive
international intervention occurs, a meaningful introduction of
HPV vaccines worldwide will take decades. As a sequitur, for most
living women today, screening remains their primary option for
cervical cancer prevention. The momentum afforded by the arrival
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attention to the potential of HPV screening technology as
compared to conventional cytology, a scientific evidence that in
spite of consistent findings in a number of clinical trials has been
only irregularly followed in a significant number of the developed
countries.
ADVANCES IN SCREENING
After 50 years of Pap smears and close to a decade of evaluation of
HPV-based screening, a number of considerations on its value and
sustainability have been concluded by several major international
review parties (International Agency for Research on Cancer, 2005;
Arbyn et al, 2006; Cuzick et al, 2006b; Kitchener et al, 2006).
It is important to recognise upfront that in selected countries,
reductions of up to 70% in cervical cancer incidence and mortality
have been achieved by repeated conventional cytology screening
tests. The successful screening programmes are usually centralised
and coordinated by the public health systems and require
consistent compliance of the population. In developed countries
with opportunistic generalised screening and mixed activities in
the public and private sectors, some subpopulations are largely
over screened and eventually over treated. In many instances, the
system is expensive and inefficient. If HPV vaccines are primarily
used and/or limited to these populations, the global impact of
vaccination on cervical cancer rates will be marginal. If, in
addition, current screening practices are maintained, the system
will become even more expensive and inefficient.
In the majority of countries in the world, the three-stage
conventional screening for cervical cancer (Pap smear, colpo-
scopy/biopsy and treatment) repeated at regular intervals has not
been sustainable, and active research is in place to evaluate
screening alternatives (Denny et al, 2006).
Second, over 15 studies have consistently shown that the use of
HPV DNA tests as the primary screening method is significantly
more sensitive than cytology-based screening, either conventional
or liquid based (International Agency for Research on Cancer,
2005; Cuzick et al, 2006a; Ronco et al, 2006; Mayrand et al, 2007).
The summary gain in sensitivity is in the range of 25–35%, and the
reasons for it are clearly understood: (a) the presence of HPV DNA
is a necessary prerequisite for cervical intraepithelial neoplasia
(CIN) 2þ; (b) the sensitivity of HPV tests is consistently high
(490%) across different laboratories, with an average level of
sophistication in technology; (c) the detection of HPV DNA is
independent of the limitations of any human eye observation, as it
is the case with colposcopy, cytology and histology; and (d) HPV
being often a field infection, the detection of the viral DNA is
largely independent of the sampling ability to the point that self-
sampling is able to detect HPV DNA at a similar level to that of the
professionally collected cervical sample. Additional advantages of
HPV screening refer to the automation of the process amenable to
high throughput and subsequent lower costs and the recognition
that HPV tests will be of great use in the evaluation of vaccination
programmes.
The trade off of the high sensitivity of HPV screening is a
reduced specificity in the order of 8–12% as compared with
cytology, afforded by the high specificity of the cytology test.
However, the conventional parameters of sensitivity and specificity
traditionally refer to the ability of the tests to detect prevalent
disease (cancer or the precursors) at the time of screening. Under
this concept, a woman aged 30–35 years or above found positive
for a high-risk HPV DNA and normal in the cytological
examination would be labelled as a (prevalent) false positive,
weighing against specificity. Longitudinal studies have shown,
however, that these cases (might be as high as 10% of screening
participants) particularly if HPV DNA persists are indeed at higher
risk of progression to CIN 2þ within the next decade as compared
to women who show normal cytology and are HPV negative
(Lorincz and Richart, 2003; Kjaer et al, 2006). Clinically, these
women are properly identified as part of the high-risk group
and candidate to more intense follow-up. Moreover, the
10-year positive predictive value for CIN 2þ is almost entirely
due to the HPV tests, largely arguing in favour of using HPV as
the stand-alone primary screening test and taking advantage of the
higher specificity of cytology/biopsy to triage HPV-positive women
(after ages 30–35 years) and to guide management. The
classification of the population in terms of risk is indeed
the object of screening, and therefore, the longitudinal predictive
value should be increasingly used to evaluate HPV testing as
primary screening test.
At present, cocktail testing for 13 high-risk HPV types with
Hybrid Capture 2 is the first clinically validated system and widely
used in some countries. However, based upon more recent data
showing the most aggressive natural history of HPV 16 and 18 as
compared to the remaining high-risk HPV types, current
discussions are considering the introduction of type-specific
HPV tests in screening and clinical management (International
Agency for Research on Cancer, 2005; Khan et al, 2005; Schiffman
and Castle, 2005; Arbyn et al, 2006; Cuzick et al, 2006a).
SUSTAINABLE SCREENING AND THE POLITICAL
ACCEPTABILITY
The decades of the 1990s and 2000s have also witnessed trials on
the use of low technology options to introduce screening in
populations that lack the essential social and health structures
required to make screening a success. In some instances, the lack
of screening also reflects to the lack of political will to prioritise
Table 2 Selection of current research priorities to accelerate HPV vaccine arrival to high-risk countries for cervical and other genital cancers
K Continue generating estimates of the burden of HPV and related cancer. This is particularly important in developing areas, where health statistics are of limited
completeness and are likely to underestimate the extend of the cancer burden in women
K Advance in the modelling exercises at a regional level to help estimate the incidence of cervical cancer from HPV surveys
K Complete trials of HPV vaccines in infants with a view to its incorporation into the existing vaccination programmes
K Complete trials of HPV vaccines in men. Studies on the potential negative impact of a gender-specific vaccination. Vaccine acceptability in different cultures should
be completed
K Complete trials in the immunosuppressed to guide use of HPV vaccines and vaccine choice in countries with high prevalence of HIV and malaria
K Complete trials in women above the age of 26 years to estimate the full impact of strategies that include massive vaccination campaigns of women aged 9–45+
years
K Include in the Phase IV trial designs the evaluation and rationalisation of the catch-up strategies in adult women that will occur in developed countries
K Complete the evaluation of the impact of HPV-type-specific cross protection of current vaccines and continue research into polyvalent vaccines covering a wider
spectrum of the cancer-causing HPV types
K Advance in the evaluation of sustainable alternatives for screening in developing countries
K Advance in the models for integration of HPV vaccines and in the definition of subsequent screening programmes for the surveillance of vaccinated women
HPV¼human papillomavirus.
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as largely linked to the technology itself, but screening is a public
health concept closely related to socioeconomic development, and
therefore, changing technology does not guarantee a successful
screening programme. For example, a number of observations in
developing countries have shown that in addition to a very limited
and socially selected screening coverage, a significant fraction of
the failures refer to the inadequate follow-up of women with
abnormal cytology. These are issues of country development, of
availability and population access to medical facilities for
diagnostics and treatment and, in more general terms, of
sustainable health services and social equity (Denny et al, 2006).
Research on visual inspection methods (VIA), self-sampling
strategies for HPV DNA, reduction of screening protocols to two-
step (screen and treat) rather than three-step (screen, diagnose and
treat), and development of lower cost, lower technology screening
tests for HPV is ongoing, and results have already been reported.
In Peru, comparisons were made between conventional cytology,
liquid-based cytology, VIA and HPV testing (laboratories for HPV
tests were out of the country). The study concluded that a strategy
involving HPV testing as the primary screening test was the best
option, provided that local infrastructure is developed and new
HPV testing methods that result in lower cost are used (Almonte
et al, 2007). In India, a VIA programme was effective in reducing
the incidence of cervical cancer, of advanced cervical cancer and of
mortality due to cervical cancer (Sankaranarayanan et al, 2007).
Operational research should carefully consider strategies that
would broaden the age ranges of the preventive interventions to
accommodate logistics and health-care structures in place. For
example, programmes could jointly offer HPV vaccine to
adolescents (or to infants) and some form of screening to their
mothers during the vaccination sessions already in place in most
developing countries.
More recently, mathematical models are exploring alternative
strategies that combine the power of vaccination to simplified
screening schemes towards strategies that are sustainable in their
context (Garnett et al, 2006; Raffle, 2007).
Several of such studies have been published for developed and
developing countries, and estimates of the threshold costs of the
vaccine are being produced to make them attractive to most
populations. For example in Brazil, a cost of less than 25
international dollars per vaccinated girl aged less than 12 years
of age followed by three screening rounds over lifetime in the
intervals 35–45 would be considered very cost-effective under
standard criteria (Goldie et al, 2007).
VACCINATION OR SCREENING, VACCINATION AND
SCREENING
It seems plausible that HPV vaccines will be, on the long run, the
answer to cervical cancer and likely the answer to most of the other
cancers of the female and male external genital tract. Once the
extent of the cross protection is understood and/or additional HPV
types are incorporated into the vaccines, the requirements for
screening will be further reduced and eventually eliminated. In the
interim, HPV vaccination should be made available to most
women. The reasoning for it is several fold:
Susceptibility by age
At any given point in time, the prevalence of HPV 16 and/or 18
among women participating in screening activities is low (less that
3% in most populations) and of women exposed to both 16 and 18
is less that 1%. The lifetime cumulative exposure to any of these
two viral types is in the order of 20% in high-risk populations.
Therefore, the vast majority of women remain susceptible to new
infections throughout their sexually active life. Vaccines including
HPV 6 and 11 will further increase their attraction for the
prevention of genital warts (GWs) in sexually active women and
possibly among men as well (Dunne et al, 2007).
Efficacy by age
Human papillomavirus vaccines are efficacious in all age groups
within the 15–26 years range. Although there are not at present
individual studies reporting on HPV vaccine efficacy in sexually
active adult after age 26 years, or broken down by age groups to
investigate efficacy trends by age, the combined results from Phase
III trials have shown anecdotal CIN 2þ cases in the vaccinated
women (usually in the context of lesions with multiple HPV types),
and, therefore, one could assume that protection is consistent in
the 15–26 years range (Paavonen et al, 2007; The Future II Study
Group, 2007). The Future II study has reported on an ‘intention-to-
treat’ analysis in which women were included in the study
irrespective of their HPV and cytology status at entry (except in
the presence of HSIL requiring diagnostic and treatment). End
points were CIN 2/3 cases related to one out of the four HPV types
included in the vaccine (6, 11, 16 and 18) and were counted as from
day 1 after first injection. A sizable proportion of women were
HPV positive at entry (9% to HPV 16 and 4% to HPV 18) and/or
had an abnormal cytology (ASCUS and LSIL combined 10.5%)
both in the vaccinated and control groups. In these women, the
efficacy of the vaccine was estimated at 44% (95% CI: 26–58). The
equivalent efficacy estimates in the ‘per protocol’ populations was
98% (95% CI: 86–100). The reduction in the observed efficacy
estimate should be interpreted as the absence of any therapeutic
effect when HPV DNA-positive women are vaccinated rather than
any putative-reduced biological response linked to age. This
interpretation is consistent with the results showing no effect on
HPV prognosis in women receiving the bivalent vaccine (Hilde-
sheim et al, 2007). Ongoing trials should provide the necessary
evidence on efficacy for women above the age of 26 years. Cost-
effective analyses examining the impact of age at vaccination in the
presence of variable underlying HPV prevalence rates by country
and age should clarify in the near future the opportunities linked
to vaccination of middle-aged sexually active women.
Immunogenicity by age
The vaccines are immunogenic in a wide age range. Bridging
studies have shown that vaccinating women in the age groups 26
years and above induces universal antibody response and,
although the antibody titres are significantly lower as women
age, they remain at a significantly higher level than the titres
induced by natural infection; moreover, more indication of
immune memory in the quadrivalent vaccine trial has been
reported (Olsson et al, 2007). Although to date, no correlate of
protection can be linked to antibody titres, largely from animal
experiments it is generally accepted that antibody production and
protection from infection are interrelated.
Safety by age
Human papillomavirus vaccines are safe in the 15–26 age range
and within the limits of 6–7 years of follow-up (http://
www.who.int/vaccine_safety/en/; GACVS, 2007). There is so far
no indication that safety concerns might arise in the elderly, but
again, this is an issue to be answered by ongoing trials and Phase
IV long-term follow-up on millions of persons.
Over the predicted fraction of cervical cancer cases unrelated to
16 or 18 that will continue to occur in vaccinated women, an
important key consideration for the integration of HPV vaccines
into existing screening efforts, including women up to 45–50 years
is that these vaccines are not therapeutic (Hildesheim et al, 2007;
The Future II Study Group, 2007). Therefore, when vaccinating
HPV and cervical cancer
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neoplastic process (women either persistent HPV positive or with
prevalent lesions) is identified by adequate screening. However,
ruling out underlying infection with the HPV types included in the
vaccine is not a prerequisite for vaccination, since less that 1% of
women would be excluded from vaccination based upon a positive
test for HPV 16 and 18 DNA. It will also be important to explain to
women the need to continue surveillance for cervical neoplasia
after vaccination and that the promise of a 70% protection against
cervical cancer only applies fully to HPV 16, 18-negative women at
the time of vaccination.
Continue screening, yes but how?
While cytology remains as the primary screening option, scientific
evidence already available suggests that follow-up after HPV
vaccination should drift over time towards a generalised adoption
of the new generation screening protocols, largely based upon the
detection (and typing) of HPV DNA. The interest of these new
protocols, in which the advantages of an HPV test over cytology in
terms of sensitivity and positive predictive value are fully
recognised, is further enhanced by the understanding that after
eliminating HPV 16 and 18 from the spectrum of HPV infections
and related lesions in vaccinated adolescents, the performance of
the cytology as screening test will be further reduced (Franco et al,
2006). In a context in which women are and will continue to be
regularly followed up, one could argue that the screening test used
(cytology or HPV tests) may not represent a significant alternative,
other than the costs of the number of visits and the need of
repeated examinations generated by each technology. However,
current scientific evidence clearly recommends to use as a first-line
screening test the most sensitive – HPV DNA testing – and to use
the most specific – cytopathology – for triage and diagnosis. In
many parts of the world, screening alternatives that require fewer
visits are essential, and models calibrated to developed countries
are being developed to guide public health decisions in defining
the appropriate and cost-effective strategies for genital cancer
prevention (Kim et al, 2005; Garnett et al, 2006; Elbasha et al,
2007).
On medical grounds, even if HPV vaccination would achieve a
similar level of mortality reduction as currently achieved by
organised screening programmes (i.e., close to 70%), primary
prevention of cervical lesions has significant clinical and human
advantages over secondary prevention, because it avoids most of
the uncertainties and unwanted side effects of cytology-based
screening programmes. These include the requirement of frequent
and repeated visits of millions of women with a normal cervix, the
4–5% uncertain cytological results (ASCUS and others) requiring
additional diagnostic protocols, the often required biopsies and the
eventual surgical treatments for conditions that otherwise would
regress spontaneously in a sizeable proportion (i.e., most of the
CIN 2 cases). The latter, a direct consequence of some of the most
recent classifications of cervical lesions (i.e., the Bethesda System),
has repeatedly been linked to unwanted obstetrics consequences
(Kyrgiou et al, 2006).
THE IMPACT OF GENITAL WARTS IN THE
SCREENING/VACCINATION SCENARIO AND THE
PREVENTION OF OTHER GENITAL CANCERS
One of the two vaccines available includes HPV 6 and 11 antigens
and has shown high efficacy against external GWs (Garland et al,
2007). The prevalence of GW has been estimated at 1% of the
sexually adult population, is common in young persons and
represents a significant burden to health services. The economic
impact of GW is being evaluated, and it is anticipated that the
quadrivalent vaccine will offer a significant advantage on these
grounds, over and above, the cancer prevention potential (Elbasha
et al, 2007). Finally, the quadrivalent vaccine has already
shown high efficacy against the preneoplastic lesions of the vulva
(VIN 2/3) and vagina (VAIN 2/3) related to HPV 16 and 18. At
present, screening for these conditions is erratic and no organised
activities are in place even in developed countries with centralised
cervical cancer screening programmes. Therefore, prevention of
these cancers represents a net significant advantage of current
HPV vaccines over screening protocols. Results from the bivalent
HPV vaccine have not yet been reported.
THE CHALLENGE AND THE ORGANISATION
The tools and the momentum seem now ready to redesign novel
strategies for cervical cancer prevention in developed and
developing countries and populations. The axes of action seem
to call for efforts in at least four directions:
Research for intervention
Table 2 summarises some of the activities that are important to
accelerate the successful introduction of HPV vaccines in the
different scenarios in the world.
Education
Both professional and public need to renew and increase
awareness on the burden of disease and the new opportunities
for prevention. Educational messages need to understand the
complexities of a vaccine against a sexually transmitted infection,
and the cultural specificities that have to be considered to ensure
acceptability and high uptake.
Financial support
Continue the work initiated by a number of institutions and
funding agencies to ensure that support is being directed to
make full use of these new opportunities. Cervical cancer
might not be regarded as a social priority in some countries if
compared to other vaccines or therapies for the prevention of
more prevalent conditions such as malaria or AIDS. However,
excellent HPV vaccines are the feasible option now and all efforts
have to be made to integrate them into the vaccine delivery
schemes.
Coordination
The arrival of a new vaccine is a complex interdisciplinary exercise
requiring different social abilities and expertise. Multiple partial
initiatives are under way, and coherence in the messaging and
programme development should be viewed as an advantage. This
refers to the management of information, addressing research
issues and deploying the network and the logistics to reach women
in the world.
CONCLUSION
The qualitative new protocols for cervical cancer prevention
after the seminal work of Papanicolaou are now being written,
taking full advantage of the HPV-based technology for screening
and vaccination. The deployment of such protocols has the
potential to complete Papanicolaou’s goal of cervical cancer
eradication by extending the benefits of prevention to the
developing populations of the world.
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